Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma

Journal of Hepatology

Volumn 49, Issue 6, 2008, Pages 946-954

  Mizukoshi, Eishiro ^a   Honda, Masao ^a   Arai, Kuniaki ^a   Yamashita, Tatsuya ^a   Nakamoto, Yasunari ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cancer; CD8; Hepatitis; HLA A24; Immune response

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 3; TUMOR ANTIGEN;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; BLOOD SAMPLING; CANCER TISSUE; CELL ISOLATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOTHERAPY; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; TUMOR ASSOCIATED LEUKOCYTE;

AGED; BIOPSY; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC;

EID: 55549148390     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.05.012     Document Type: Article

References (35)

1. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. Lin S.M., Lin C.J., Lin C.C., Hsu C.W., and Chen Y.C. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 127 (2004) 1714-1723
3. Ercolani G., Grazi G.L., Ravaioli M., Del Gaudio M., Gardini A., Cescon M., et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237 (2003) 536-543
4. Omata M., Tateishi R., Yoshida H., and Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 127 (2004) S159-S166
5. Butterfield L.H., Ribas A., Meng W.S., Dissette V.B., Amarnani S., Vu H.T., et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 9 (2003) 5902-5908
6. Shang X.Y., Chen H.S., Zhang H.G., Pang X.W., Qiao H., Peng J.R., et al. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res 10 (2004) 6946-6955
7. Zerbini A., Pilli M., Soliani P., Ziegler S., Pelosi G., Orlandini A., et al. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J Hepatol 40 (2004) 102-109
8. Komori H., Nakatsura T., Senju S., Yoshitake Y., Motomura Y., Ikuta Y., et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12 (2006) 2689-2697
9. Mizukoshi E., Nakamoto Y., Tsuji H., Yamashita T., and Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 118 (2006) 1194-1204
10. Mizukoshi E., Nakamoto Y., Marukawa Y., Arai K., Yamashita T., Tsuji H., et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43 (2006) 1284-1294
11. Borst P., and Elferink R.O. Mammalian ABC transporters in health and disease. Annu Rev Biochem 71 (2002) 537-592
12. Kiuchi Y., Suzuki H., Hirohashi T., Tyson C.A., and Sugiyama Y. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett 433 (1998) 149-152
13. Yamada A., Kawano K., Koga M., Matsumoto T., and Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 61 (2001) 6459-6466
14. Tada Y., Wada M., Migita T., Nagayama J., Hinoshita E., Mochida Y., et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 98 (2002) 630-635
15. Young L.C., Campling B.G., Cole S.P., Deeley R.G., and Gerlach J.H. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7 (2001) 1798-1804
16. Nies A.T., Konig J., Pfannschmidt M., Klar E., Hofmann W.J., and Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 94 (2001) 492-499
17. Zollner G., Wagner M., Fickert P., Silbert D., Fuchsbichler A., Zatloukal K., et al. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 25 (2005) 367-379
18. Araki T., Itai Y., Furui S., and Tasaka A. Dynamic CT densitometry of hepatic tumors. AJR Am J Roentgenol 135 (1980) 1037-1043
19. Liver cancer study group of Japan. General rules for the clinical and pathological study of primary liver cancer. Second English Edition. Kanehara & Co., Ltd., Tokyo. 2003.
20. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., and Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 (1994) 1513-1520
21. Oiso M., Eura M., Katsura F., Takiguchi M., Sobao Y., Masuyama K., et al. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int J Cancer 81 (1999) 387-394
22. Honda M., Yamashita T., Ueda T., Takatori H., Nishino R., and Kaneko S. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 44 (2006) 1122-1138
23. Mizukoshi E., Nascimbeni M., Blaustein J.B., Mihalik K., Rice C.M., Liang T.J., et al. Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies. J Virol 76 (2002) 6093-6103
24. Ikeda-Moore Y., Tomiyama H., Miwa K., Oka S., Iwamoto A., Kaneko Y., et al. Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. J Immunol 159 (1997) 6242-6252
25. Kuzushima K., Hayashi N., Kimura H., and Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 98 (2001) 1872-1881
26. Zerbini A., Pilli M., Penna A., Pelosi G., Schianchi C., Molinari A., et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 66 (2006) 1139-1146
27. Ayaru L., Pereira S.P., Alisa A., Pathan A.A., Williams R., Davidson B., et al. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol 178 (2007) 1914-1922
28. Konig J., Hartel M., Nies A.T., Martignoni M.E., Guo J., Buchler M.W., et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 115 (2005) 359-367
29. Steinbach D., Wittig S., Cario G., Viehmann S., Mueller A., Gruhn B., et al. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 102 (2003) 4493-4498
30. Komohara Y., Harada M., Arima Y., Suekane S., Noguchi M., Yamada A., et al. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. Int J Oncol 29 (2006) 1555-1560
31. Nagorsen D., Keilholz U., Rivoltini L., Schmittel A., Letsch A., Asemissen A.M., et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 60 (2000) 4850-4854
32. Griffioen M., Borghi M., Schrier P.I., and Osanto S. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay. Int J Cancer 93 (2001) 549-555
33. Rentzsch C., Kayser S., Stumm S., Watermann I., Walter S., Stevanovic S., et al. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res 9 (2003) 4376-4386
34. Oguri T., Isobe T., Fujitaka K., Ishikawa N., and Kohno N. Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer 93 (2001) 584-589
35. Steinbach D., Lengemann J., Voigt A., Hermann J., Zintl F., and Sauerbrey A. Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res 9 (2003) 1083-1086